// App-Quantinova.ai

1921 : Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosomea-Positive Chronic Myeloid Leukemia

Researchers

Presenter

  • Vamsi Kota

Principal Investigators

  • Tim H. Brummendorf

  • Carlo Gambacorti-Passerini

  • Mark Shapiro

  • H. Jean Khoury

  • Jorge E. Cortes

  • Jeffrey H. Lipton

  • Hagop M. Kantarjian

  • Dong-Wook Kim

  • Fiona An

  • Eric Leip

  • Rocco J. Crescenzo

  • Mabel Woloj

Medical Centers

  • S. Gerardo Hospital, University of Milano Bicocca, Monza, Italy

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Uniklinik RWTH Aachen, Aachen, Germany

  • Winship Cancer Inst, Atlanta, GA

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

  • Germany

  • Italy

  • Canada

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Bosutinib

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved